Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Creatine

Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers

Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer

Ziftomenib in Relapsed or Refractory NPM1-Mutant AML

Advanced Biliary Tract Cancer Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin